eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
5/2018
vol. 4
 
Share:
Share:
more
 
 
abstract:
Review paper

Vildagliptin and cardiovascular risk factors – safety of therapy, drug interactions

Marcin Wełnicki
,
Artur Mamcarz

Online publish date: 2018/11/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Type 2 diabetes is a very serious problem of public health. Together with cardiovascular diseases, diabetes is responsible for most premature deaths all over the word. The latest guidelines prefer usage of antihyperglycaemic drugs with additional positive cardiovascular profile. DPP-4 inhibitors and vildagliptin among them for more than 10 years were studied also under those circumstances. In this article we will try to sum up the main studies as far as the cardiovascular safety of vildagliptin is concerned.
keywords:

vildagliptin, type 2 diabetes, cardiovascular risk

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe